Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma

This study is testing pembrolizumab — an immunotherapy drug — for adults with advanced cutaneous sarcomas (a type of cancer that starts in the skin or tissue just beneath the skin), excluding a specific subtype called angiosarcoma. The trial aims to determine whether this drug can slow or stop the growth of these rare, hard-to-treat cancers. **You may be eligible if...** - You are 18 years or older - You have a confirmed diagnosis of soft tissue sarcoma with a cutaneous (skin/dermis) primary site - Your cancer has spread, come back, or cannot be safely removed by surgery - You have at least one measurable tumor on imaging - You have available tumor tissue for analysis - It has been at least 4 weeks since your last cancer treatment **You may NOT be eligible if...** - Your sarcoma is an angiosarcoma - You have active autoimmune disease requiring systemic treatment - You have uncontrolled infections or significant medical conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.